VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ICML 2019 | Zanubrutinib plus obinutuzumab: CLL, SLL & FL

Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of zanubrutinib plus obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed/refractory follicular lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter